The importance of detecting postmarketing safety signals earlier and with a high degree of fidelity is increasingly important and of great interest to industry, regulators, and the public. This issue of Clinical Pharmacology & Therapeutics contains two companion articles that represent exciting new advances in the field of pharmacovigilance and postmarketing safety signal detection. Given that drug safety evaluation and pharmacovigilance science are core competencies in the discipline of clinical pharmacology, these articles should be of interest to clinical pharmacologists as well as drug safety professionals.